The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials
Introduction: The efficacy of liraglutide to treat heart failure remains controversial. We conducted a systematic review and meta-analysis to explore the influence of liraglutide on heart failure.
Methods: We searched PubMed, EMbase, Web of Science, EBSCO, and Cochrane library databases through March 2018 for randomized controlled trials (RCTs) assessing the effect of liraglutide on cardiac function of heart failure. Meta-analysis is performed using the random-effect model.
Results: Four RCTs involving 629 patients are included in the meta-analysis. Overall, compared with the control group for heart failure, liraglutide treatment significantly can reduce NT-proBNP (Std. MD = -3.06; 95% CI = -5.78 to -0.34;
P = .03), and improve 6MWT (Std. MD=1.10; 95% CI = 0.75 to 1.44; P < .00001), but has no remarkable influence on LVEF change (Std. MD=1.10; 95% CI = -1.97 to 3.98;
P = 0.51), LVEDV change (Std. MD = 6.26; 95% CI = -1.45 to 13.97; P = .11), LVESV change (Std. MD = -13.47; 95% CI = -31.04 to 4.10; P = .13), hospitalization for heart failure (RR = 1.18; 95% CI = 0.88 to 1.58; P = .27), major adverse cardiovascular events (RR = 1.55; 95% CI = -0.24 to 9.89; P = .64), and cardiac death (RR = 1.11; 95% CI = 0.61 to 2.04; P = .72).
Conclusions: Liraglutide treatment has an important ability to reduce NT-proBNP and improve 6MWT for heart failure, but shows no important influence on LVEF, LVEDV, LVESV, hospitalization for heart failure, major adverse cardiovascular events, and cardiac death.
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. 2018. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. The lancet Diabetes & endocrinology. 6:105-13.
Bonsu KO, Arunmanakul P, Chaiyakunapruk N. 2018. Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison. Heart failure reviews.
Chanchai R, Kanjanavanit R, Leemasawat K, Amarittakomol A, Topaiboon P, Phrommintikul A. 2018. Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic. Journal of drug assessment. 7:8-13.
Chang G, Zhang D, Yu H, Zhang P, Wang Y, Zheng A, et al. 2013. Cardioprotective effects of exenatide against oxidative stress-induced injury. International journal of molecular medicine. 32:1011-20.
Chatterjee P, Joynt Maddox KE. 2018. US National Trends in Mortality From Acute Myocardial Infarction and Heart Failure: Policy Success or Failure? JAMA cardiology.
Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, et al. 2015. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. American heart journal. 170:845-54.
Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, et al. 2016. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 52:516-26.
Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, et al. 2016. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. International journal of cardiology. 208:109-14.
Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. 2011. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 43:300-5.
Drucker DJ. 2006. The biology of incretin hormones. Cell metabolism. 3:153-65.
Halbirk M, Norrelund H, Moller N, Holst JJ, Schmitz O, Nielsen R, et al. 2010. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American journal of physiology Heart and circulatory physiology. 298:H1096-102.
Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. 2017. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. The Cochrane database of systematic reviews. 5:CD012204.
Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 21:1539-58.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. 1996. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials. 17:1-12.
Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. 2017. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. European journal of heart failure. 19:69-77.
Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, et al. 2003. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 24:569-78.
Kjaergard LL, Villumsen J, Gluud C. 2001. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses. Annals of Internal Medicine. 135:982-9.
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. 2016. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Jama. 316:500-8.
Matsushita K, Harada K, Miyazaki T, Miyamoto T, Iida K, Tanimoto S, et al. 2018. Effects of glycemic control on in-hospital mortality among acute heart failure patients with reduced, mid-range, and preserved ejection fraction. Heart and vessels.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology. 62:1006-12.
Munaf M, Pellicori P, Allgar V, Wong K. 2012. A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure. International journal of peptides. 2012:249827.
Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. 2017. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 136:849-70.
Nielsen R, Jorsal A, Iversen P, Tolbod LP, Bouchelouche K, Sorensen J, et al. 2017. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
Nguyen TD, Shingu Y, Amorim PA, Schenkl C, Schwarzer M, Doenst T. 2018. GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction. Journal of cardiovascular translational research.
Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 58:975-83.
Packer M. 2017. Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? European journal of heart failure.
Packer M. 2018. Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure? Journal of cardiac failure. 24:109-11.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine. 341:709-17.
Santulli G. 2012. Coronary heart disease risk factors and mortality. Jama. 307:1137; author reply 8.
Scheen AJ. 2017. GLP-1 receptor agonists and heart failure in diabetes. Diabetes & metabolism. 43 Suppl 1:2S13-2S9.
Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, et al. 2016. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. Circulation. 134:1339-52.
Takahashi A, Ihara M, Yamazaki S, Asanuma H, Asakura M, Kitakaze M. 2015. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure. International heart journal. 56:372-6.
Tang ZH, Wang L, Zeng F, Zhang K. 2014. Association and predictive value analysis for metabolic syndrome on systolic and diastolic heart failure in high-risk patients. BMC cardiovascular disorders. 14:124.
Ussher JR, Drucker DJ. 2014. Cardiovascular actions of incretin-based therapies. Circulation research. 114:1788-803.
Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. 2018. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction. JAMA cardiology.
Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, et al. 2013. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circulation Heart failure. 6:1039-48.
Zhang JY, Wang XY, Wang X. 2017. Effects of liraglutide on hemodynamic parameters in patients with heart failure. Oncotarget. 8:62693-702.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).